Abstract
INTRODUCTION
Bioprosthetic heart valve prostheses are being implanted at an increasing rate as the population ages. However, the durability of the prostheses is increasingly coming under scrutiny because patients are surviving longer. The advent of transcatheter aortic valve implantation (TAVI) has, in some ways, perhaps alleviated the problem, with 'valve-in-valve' TAVI as a potential therapy for a failing prosthesis. Nevertheless, TAVI has also stimulated more patients to choose a biological prosthesis at a younger age in the expectation that a subsequent TAVI can be deployed later if required. The long-term performance of TAVI prostheses is of some concern so the durability of the initial xenograft implant remains of paramount importance.
Valve companies have tackled the issue of durability in different ways. Medtronic introduced the Mosaic prosthesis in 1994, with a novel anticalcification treatment and zero pressure fixation, aimed at preserving the natural geometry of the collagen fibres. Edwards Life Sciences produced the Carpentier-Edwards supra-annular aortic valve (CE-SAV) in 1982 with a new stent design that facilitated wider opening of softer leaflets, which were preserved under low pressure.
The cardiothoracic unit at Derriford Hospital Plymouth set out to compare the efficacy of these 2 designs in a prospective randomized controlled trial to compare directly the clinical performance and long-term durability of the newer Mosaic bioprosthesis and the CE-SAV bioprosthesis in the aortic position. The primary outcomes evaluated were valve-related mortality and morbidity, including freedom from reoperation, structural valve degeneration, paravalvular leaks and thromboembolic events. Both prostheses were in widespread use when the trial began, and all surgeons in the unit were happy to randomize their patients to one or the other of the treatment arms.
MATERIALS AND METHODS

Patient selection
The recruitment of patients, the methods and the study protocol for this trial were reported previously [1] . Approval was obtained from Derriford Hospital's ethics committee. A total of 394 patients undergoing porcine xenograft aortic valve replacement were recruited from 2001 to 2005. All patients who required bioprosthetic aortic valve replacement with or without coronary artery bypass grafting (CABG) during this period were considered. Patients who underwent concomitant procedures other than CABG were excluded. Patients with an illness other than valve disease that would considerably increase mortality rates within the 1st year were also excluded. All patients provided written informed consent.
Sample size was determined using an estimation of both structural valve deterioration (SVD) and number lost to follow-up over the 10-year period. Log-rank test analysis predicted that approximately 82% from the CE-SAV and 92% from the Mosaic group would not experience SVD. We expected to lose 30% from each group. A 2-tailed test with a P-value of <0.05 and a power of 80% required a sample size of no less than 180 patients per valve [1] .
Randomization
All enrolled patients were prospectively randomized to receive either a CE-SAV or a Medtronic Mosaic valve after induction of anaesthesia in the operating theatre. There was no blinding because products were identifiable at surgery, and there were no crossovers due to individual surgeon preference. Patients were allocated to their treatment groups using a method of minimization, to ensure that the prognostic determinants of outcome were equally represented in both groups, rather than allocating them solely on chance [2] . The stratification variables determined in our study were age, sex, concomitant CABG, left ventricular function, cause of valve disease (stenosis, insufficiency, mixed), history of myocardial infarction and hypertension.
Data collection
The guidelines outlined by the American Association for Thoracic Surgeons, the European Association for Cardiothoracic Surgery and the Society of Thoracic Surgeons were used to define and report mortality and morbidity [3] .
Data for each patient involved in the study were collected at the preoperative stage, at the intraoperative stage, at follow-up after hospital discharge and at a later annual follow-up by the research nurse, who used a clinical record form designed when the trial began. Any death of a discharged patient occurring within 30 days of implantation or death of a patient at any time before discharge after implantation was considered early mortality. Transfer to another hospital was not included as a discharge.
Valve-related complications were reported and comprised thromboembolism, SVD, non-structural valve dysfunction (non-SVD) and prosthetic valve endocarditis. SVD was defined as a primary valve-related defect (e.g. leaflet deterioration, leaflet calcification and cusp wear/abrasion) in the function of the prosthetic valve that resulted in stenosis or regurgitation that was shown through reoperation, autopsy or clinical evaluation not to be due to infection or thrombosis. Non-SVD was classified as an altered function of the prosthetic study valve, not intrinsic to the valve (entrapment by pannus, tissue, suture, paravalvular leak, inappropriate sizing or positioning and clinically important haemolytic anaemia) and not including endocarditis and thrombosis. Definitions for non-SVD events included (i) primary paravalvular leak occurring in the presence of any blood leakage from the prosthesis between the sewing ring and the native annulus and (ii) leaflet impingement/entrapment, secondary to tissue, suture or other external factors causing stenosis or regurgitation, with evidence seen at reoperation.
Surgical technique
Following a median sternotomy, valve implantation in all patients occurred during full cardiopulmonary bypass at 32 C. Antegrade cold blood cardioplegia was used for myocardial protection. All surgeons used a semicontinuous suture with 2-0 polypropylene sutures apart from 2 who used a non-everting mattress suture technique with 2-0 Ti-Cron (Covidien, Mansfield, MA, USA).
Statistical analysis
All patient data were prospective and recorded in an Excel database. Continuous variables pertaining to patient demographics, total cohort number, mean, mode, median and standard deviation are presented. Their means were compared using a 2-sample t-test. Categorical variables are provided in the form of numbers and percentages. Given n >200 patients, their proportions were compared using a standard z-hypothesis test (normal approximation). Statistical analyses were conducted using the Statistical Package for the Social Sciences (SPSS) software (version 19.0. Armonk, NY, USA) to generate Kaplan-Meier graphs for assessment of survival. The survival plots were compared using a log-rank test. MiniTab statistical software was used to produce P-values and confidence intervals (CIs). A P-value of <0.05 was considered statistically significant.
Registration
This trial is registered at clinicaltrials.gov (Registration number: NCT03346044).
RESULTS
Between January 2001 and March 2005, 402 patients at The
South West Cardiothoracic Unit, Derriford Hospital, UK, were assessed for eligibility and randomized into the xenograft trial. Three patients who had active endocarditis or concomitant procedures other than a CABG at the time of the aortic valve replacement were excluded. A total of 191 patients receiving the CE-SAV (3 lost to follow-up) and 203 patients in the Mosaic cohort (2 lost to follow-up) were analysed. The remainder received telephone follow-up calls based on the annual clinical record form, with 100% success. The CONSORT flow diagram is shown in Fig. 1 .
CE-SAV prostheses were implanted into 191 patients (103 men and 88 women). Medtronic's Mosaic prosthesis was implanted into an additional 203 patients (121 men and 82 women). The mean patient age was 75.34 (SD 7.06 years; range 40-91 years) in the CE-SAV group and 74.30 (SD 6.20 years; range 51-91 years) in the Mosaic group (P = 0.12). Preoperative demographics, additive EuroSCORE and intraoperative characteristics concerning cardiopulmonary bypass were comparable between the 2 groups (Table 1) . Concomitant CABG was performed in 91 (47.6%) patients in the CE-SAV group and 106 (52.2%) patients in the Mosaic group (P = 0.36). Two patients had histories of previous endocarditis in both the CE-SAV and Mosaic cohorts. In this data set, the total follow-up was 2869 patient-years. The median followup was 9.01 years (25th-75th percentile 5.01-10.01 years) (when deceased patients were included). Among survivors, the median follow-up was 10.01 years (25th-75th percentile 9.88-10.05 years).
Survival comparison
There were 77 (40.3) deaths in the CE-SAV group and 93 (45.8%) deaths in the Mosaic group (P = 0.27). The causes of deaths are given in Table 2 . There were 6 early deaths in the CE-SAV group compared to 12 in the Mosaic group (P = 0.18). At 10 years after implantation, the number of patients alive in the 2 groups was 114 and 110, respectively (P = 0.27). There was no statistically significant difference in the Kaplan-Meier plots of survival between the 2 cohorts of patients (log-rank test P = 0.241) (Fig. 2) .
Structural valve deterioration
There were 3 incidences of SVD, all of them in the Mosaic group. There was 1 case of leaflet calcification 1 year after implantation with no clear cause. This 51-year-old patient did not undergo haemodialysis or have any metabolic disorders that the calcification could be attributed to. The other 2 patients experienced regurgitant degeneration at 4 and 10 years after implantation, both of which have come from the central portion due to malcoaptation. These patients were 67 and 56 years of age, respectively.
There were no occurrences of SVD in the CE-SAV group. However, this difference between the 2 prostheses was not statistically significant (P = 0.081). Thus, the freedom from SVD at 10 years was 100% in the CE-SAV group and 98.52% in the Mosaic group.
Non-structural valve dysfunction
There were 5 cases of non-SVD, all of which were primary paravalvular leaks, and all of them were from the Mosaic cohort. This result represented a statistically significant difference in favour of the CE-SAV group (P = 0.024). 
Endocarditis
There were 2 cases of endocarditis in each of the CE-SAV and Mosaic cohorts (P = 0.951).
Thromboembolism
The difference in the incidence of thromboembolism approached significance with 31 cases in the CE-SAV group compared to 19 in the Mosaic group (P = 0.057).
Valve-related reoperation
Freedom from reoperation at 10 years was 100% in the CE-SAV group and 97.4% in the Mosaic group. There were 6 cases of valve-related reoperation, all belonging to the Mosaic group with none in the CE-SAV group, that were due to degenerated valves, endocarditis, paravalvular leak and aortic insufficiency (P = 0.013).
At 10 years after implantation, the number of patients free from reoperation was 191 in the CE-SAV cohort and 197 in the Mosaic cohort. There was a statistically significant difference in the Kaplan-Meier plots of freedom from reoperation between the 2 cohorts of patients (log-rank test P = 0.029) (Fig. 3) .
Other adverse events
The other adverse events that occurred during the 10-year period can be seen in Table 3 .
DISCUSSION
This prospective, randomized trial demonstrates the clinical performance of 2 aortic porcine xenograft valves 10 years after implantation. Leaflet calcification and subsequent degeneration disrupt haemodynamic performance and impair prosthesis durability [6] . Efforts to optimize haemodynamics and durability have led to iterative modifications in the design of prostheses. Although there is abundant literature retrospectively assessing the performance of various prostheses, prospective randomized trials like ours, comparing designs, are more scarce [7, 8] . The Kaplan-Meier plots of survival between the 2 cohorts of patients demonstrate no statistically significant difference (log-rank test P = 0.241) [5] . CE-SAV: Carpentier-Edwards supra-annular aortic valve. The CE-SAV was introduced in 1982 [9] . Design changes included advanced tissue preservation and calcium mitigation agents (polysorbate 80) to decrease the occurrence of SVD. Elgiloy metal wire stents were covered with polytetrafluoroethylene for mechanical support, and a scalloped suturing ring was designed to conform more closely to the implantation position. The porcine tissue was fixed with glutaraldehyde at a low pressure of 2 mmHg [10] .
Jamieson et al. [7] evaluated the performance of CE-SAV over a 20-year period, using actuarial and actual analysis to assess clinical outcomes. Patient survival at 15, 18 and 20 years following implantation was 28.8 ± 1.5%, 15.8 ± 1.6% and 6.8 ± 2.0% respectively. The actual freedom from SVD at 18 years was 86.4 ± 1.2% overall, 90.5 ± 1.8% for patients aged 61-70 years and 98.2 ± 0.6% for patients over 70 years. A meta-analysis reported similar figures for overall actual freedom from SVD as 89 ± 10%, with other studies supporting low rates of SVD and valve-related complications following implantation of CE-SAV [11] [12] [13] .
The Medtronic Mosaic is a third-generation porcine valve, introduced in 1994, with the goal of extending durability and enhancing haemodynamic performance. The valve design included zero pressure porcine tissue fixation with glutaraldehyde to preserve leaflet shape, whereas haemodynamic outcomes were improved with the low-profile flexible polymer stent. Mosaic valves are treated with a-amino oleic acid, an antimineralization agent, shown to be effective in reducing calcification in animal studies [6, 14] . The clinical efficacy of the Medtronic Mosaic valve has been described by Celiento et al. [15] , with actuarial survival as 82 ± 3% at 5 years, 54 ± 6% at 10 years and 48 ± 8% at 13 years. Within the 13-year period, freedom from reoperation was 86 ± 7%. Several other studies agree with the good overall performance of the Mosaic bioprosthesis, shown to have a low rate of SVD, with freedom from SVD reported as 97.4% at 8.5 years by Botzenhardt et al. [16] and 87.1% at 10 years by Riess et al. [16, 17] . In addition, age was found to be an important factor, with a lower incidence of SVD in patients aged over 70 years [18] .
Our study demonstrates results in keeping with these earlier studies but is the first to randomize the CE-SAV against the Mosaic prosthesis. The very low incidence of SVD (just 3 cases in the Mosaic group) attests to the successful incorporation of novel anticalcification and tissue fixation techniques. Our CE-SAV cohort had 100% freedom from SVD at 10 years, which compares to the results of Jamieson et al. [19] , who reported 97.6 ± 1.4% freedom from SVD for the CE-SAV aortic prosthesis at 7 years. In another paper by Jamieson et al. [20] , freedom from SVD in a cohort receiving Medtronic's Mosaic prosthesis at 6 years was reported as 98.3 ± 1.7% for their patients under 60 years of age and 100% for those over 60. These results compare well with our 98.52% freedom from SVD in the Mosaic cohort.
Several researchers reported that most cases of SVD occur late after implantation. In fact, they have shown that freedom from early SVD (<5 years after implantation) was 100% [21] [22] [23] [24] . However, in our study, 2 of the 3 cases of SVD in the Mosaic group occurred at 1 and 4 years after implantation. Nevertheless, our reported 100% freedom from SVD at 10 years in the CE-SAV group is in keeping with the reported rarity of early SVD by other groups.
Survival rates are not dissimilar between our cohorts, although it is interesting to note the differences in freedom from reoperation: 100% in the CE-SAV group and 97.04% in the Mosaic group (P = 0.013). At 5 years after implantation, 1 researcher reported Figure 3 : The Kaplan-Meier plots of freedom from reoperation between the 2 cohorts of patients demonstrate a statistically significant difference (log-rank test P = 0.029) [5] . CE-SAV: Carpentier-Edwards supra-annular aortic valve. 95.9% freedom from reoperation in patients receiving the CE-SAV prosthesis [25] . Botzenhardt et al. [16] reported 95.1% freedom from reoperation in patients receiving the Mosaic prosthesis at 8 years postimplantation. Jamieson et al. [26] studied the performance of the CE-SAV prosthesis over a longer period of 15 years and found that freedom from reoperation was 83.2 ± 1.4%. Similarly, Riess et al. [8] reported a rate of 73.3 ± 7.3% for freedom from reoperation at 13 years after implantation in a cohort receiving the Mosaic valve. These results illustrate a clear increase of valve-related reoperation risk beyond our study's 10-year time frame. The significant difference identified in our study relates to reoperation for paravalvular leaks rather than SVD. This topic is discussed below. We had 5 cases (2.5%) of non-structural valve dysfunction (NSVD) in the Mosaic group, all of which were late paravalvular leaks, compared to none in the CE-SAV group (0%) (P = 0.024). Riess et al. [8] reported an NSVD incidence of 1.6% in 255 patients receiving the Mosaic valve. Jamieson et al. [25] reported an NSVD incidence of 0.3% in 1536 patients for a cohort receiving the CE-SAV. These results echo our study's findings of a higher incidence of NSVD in the Mosaic group. Paravalvular leaks always raise concerns about endocarditis or implantation techniques.
Four of our trial's surgeons used semicontinuous Prolene sutures to implant the valves; the other 2 used interrupted mattress sutures. However, there was no relationship in this study between implant technique and the incidence of late paravalvular leaks. Four leaks occurred in the 188 implantations with semicontinuous sutures versus one in the 206 implantations with interrupted sutures (P = 0.156). There was no evidence of endocarditis in these patients, making the authors wonder whether the sewing ring design might be implicated. The fact that companies have stressed the importance of effective orifice area and transvalvular gradients as markers for haemodynamic performance has led to minimization of the sewing ring volume to maximize orifice area, which inevitably results in reduced conformability. The profiles of the 2 prostheses used in our study are quite dissimilar. The CE-SAV scalloped ring more closely matches the contours of the implantation zone and might well be the cause of the very low late leak rate seen in our study (and that of Jamieson alluded to above), compared with the more horizontal ring of the Mosaic. We speculate that the resulting tractional forces exerted on the native tissues as they are forced into this more horizontal plane might result in late annular disruption at the points of maximal stress.
We report freedom from thromboembolism at 10 years as 90.6% for the Mosaic and 84.3% for the CE-SAV (P = 0.057). Jamieson et al. [7] reported freedom from thromboembolism as 81.6% after 20 years in 1823 patients for the CE-SAV valve. Two studies have reported freedom from thromboembolism as 96.4% and 96.8% for the Mosaic valve, respectively [16, 27] . These studies align with our findings, matching the higher incidences of thromboembolism in the CE-SAV group and lower rates for Mosaic. There was no evidence of thrombosis on any of the prostheses, and, of course, thromboembolic events in this age group are not uncommon. We have not found any relationship with incidences of atrial fibrillation (73 cases in both cohorts) or anticoagulation. Our unit policy was to prescribe aspirin for patients who were discharged, only providing anticoagulants for those patients in atrial fibrillation. It remains an interesting finding but one with no easily identifiable explanation.
Limitations
All patients enrolled in our trial were offered echocardiographic follow-up at 1, 6 and 10 years after implantation. However, a substantially lower number of patients returned for their midterm echocardiographic studies and an even lower number for their final 10-year echocardiographic follow-up. This result was perhaps inevitable, given the extreme ages of our surviving patients. Therefore, sample sizes for 10-year echocardiographic data were too small to be sufficiently representative, and underreporting of SVDs is a possibility. Nevertheless, in this part of the UK, most patients live locally or are referred back to us from more distant locations [the next cardiothoracic centre is more than 100 miles (160 km) away], and we believe we would learn of most cases of SVD related to our study cohort from our cardiology colleagues and from our telephone consultations. Reoperation rates were therefore of paramount importance in this context.
CONCLUSION
In conclusion, we are pleased to report the 10-year follow-up of our prospective randomized trial comparing the CE-SAV and Medtronic Mosaic prostheses in the aortic position. Our findings are in line with those of other papers recording data about these prostheses. We were surprised to find the higher paravalvular leak rate in the Mosaic group, which strongly contributed to the lower freedom from reoperation rate in this cohort. Nevertheless, there were more thromboembolic events in the CE-SAV group, emphasizing the need for vigilance with any prosthetic design change that might bring benefits in one area at the expense of detriment in another area.
